Back to Awarded Treatment Trials
Awarded Trial: 03-RC-005-4
Grant ID
03-RC-005-4
Illness
Schizophrenia
Primary Drug/Intervention
Valacyclovir
Primary Dosage
1 g every 12 hours
Secondary Drug Intervention
N/A
Secondary Dosage
N/A
Other Drug/Intervention
N/A
Other Dosage
N/A
Status
Completed
Investigator
Dickerson
Sample Size
62
Duration of Study Period for Each Subject
16 weeks
Outcome Measurements
PANSS
Results
The goal was to use valacyclovir, an antiviral, as adjunct medication for 16 weeks for 62 patients with schizophrenia who had antibodies to cytomegalovirus (CMV) in a double-blind, placebo-controlled trial. The patients were chronic, with a mean duration of illness of 25 years. The valacylovir was well tolerated, with no SAE's attributable to the medication. However, there were no significant differences between the groups on PANSS at the end of the study.
Publication
N/A
Link
N/A
PI Name
Faith Dickerson
Degree
MD
Center
N/A
Institution
Sheppard Pratt Health System Inc.
Address
6501 N. Charles Street, P.O. Box 6815
City or Town
Baltimore
State or Province
MD
Zip or Postal Code
21285
Country
USA
Email Address
fdickerson@sheppardpratt.org